BamSEC and AlphaSense Join Forces
Learn More

Celcuity Inc.

NASDAQ: CELC    
Share price (8/19/25): $49.22    
Market cap (8/19/25): $2.088 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 3 pages Celcuity Reports Clinical Data From Two Early Phase Studies of Gedatolisib - In the Phase 1 Portion of the CELC-G-201 Clinical Trial Evaluating Gedatolisib Plus Darolutamide in Men With Metastatic Castration Resistant Prostate Cancer (“McRpc”), the Six-Month Radiographic Progression Free Survival (“Rpfs”) Rate Was 66% - In a Phase 2 Clinical Trial of Gedatolisib Plus Trastuzumab-Pkrb as 3l+ Therapy in Patients With Her2+ Metastatic Breast Cancer (“Mbc”), the Objective Response Rate (“Orr”) Was 43% - No Patients Discontinued Gedatolisib Due to a Treatment-Related Adverse Event (“Ae”) in Either Clinical Trial
12/34/56
EX-10.1
from 8-K 11 pages Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan
12/34/56
EX-10.2
from 10-Q 5 pages Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan Stock Option Agreement
12/34/56
EX-10.35
from 10-K 10 pages Celcuity Inc. Change in Control and Severance Plan and Summary Plan Description
12/34/56
EX-10.2
from 10-Q 3 pages Celcuity Inc. Non-Qualified Stock Option Transfer Agreement
12/34/56
EX-10.1
from 10-Q 1 page Amended Agreement Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan Amendment to Stock Option Agreement
12/34/56
EX-10.1
from 8-K 1 page Amendment to the Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan May 9, 2024
12/34/56
EX-10.2
from 8-K 18 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 30 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 1 page Amendment to the Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan May 11, 2023
12/34/56
EX-10.1
from 8-K ~5 pages Fourth Amendment to Lease
12/34/56
EX-10.1
from 8-K 3 pages First Amendment to Representative’s Warrant
12/34/56
EX-10.1
from 8-K 2 pages Third Amendment to Lease
12/34/56
EX-10.2
from 8-K 17 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 36 pages Securities Purchase Agreement
12/34/56
EX-10.5
from 10-Q 4 pages Amendment No. 1 to License Agreement
12/34/56
EX-10.4
from 10-Q 2 pages Second Amendment to Lease
12/34/56
EX-10.3
from 10-Q 49 pages *Certain Information Where Indicated Below in Brackets Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed* License Agreement
12/34/56
EX-10.15
from 10-K 4 pages Amendment No. 1 Clinical Trial Agreement for Fb-12 Phase II Study by and Between Nsabp Foundation, Inc. and Celcuity, Inc
12/34/56
EX-10.3
from 10-Q/A 2 pages First Amendment to Lease
12/34/56